Effects of specific STAT5a/b knockdown on cell viability and AR signalling also seem to be dependent on the cellular background of the resistant cells, reflecting the challenges of tumour heterogeneity in therapy treatment of late-stage diseases again. Here, STAT5A is linked to neoplasm.